Last reviewed · How we verify
NCT07113730
The Kinetics Profiling of Immune Reconstitution and Clinical Outcomes
trial testing immune reconstitution in Chronic Myelomonocytic Leukemia (CMML) in 300 participants. Not yet recruiting.
31 July 2035
Quick facts
| Lead sponsor | Peking University People's Hospital |
|---|---|
| Status | Not yet recruiting |
| Study type | OBSERVATIONAL |
| Enrollment | 300 |
| Start date | 13 August 2025 |
| Primary completion | 31 July 2035 |
| Estimated completion | 31 July 2036 |
Drugs / interventions tested
- immune reconstitution
Conditions studied
- Chronic Myelomonocytic Leukemia (CMML) — all drugs for Chronic Myelomonocytic Leukemia (CMML) →
- Immune Reconstitution — all drugs for Immune Reconstitution →
Sponsor
Peking University People's Hospital
Who can join
Eligibility, any sex, with Chronic Myelomonocytic Leukemia (CMML) or Immune Reconstitution. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Chronic myelomonocytic leukemia (CMML) is a clonal hematopoietic malignancy with poor prognosis. Allogeneic hematopoietic stem cell transplantation (HSCT) remains the only potentially curative treatment. Immune reconstitution (IR) is critical for improving HSCT efficacy and quality of life among survivors, yet its dynamic impact on survival and complications like chronic graft-versus-host disease (cGVHD) in CMML is poorly defined. This study aimed to investigate the dynamics of IR following HSCT in patients with CMML and evaluate its impact on post-transplant clinical outcomes.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07113730
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Chronic Myelomonocytic Leukemia (CMML)
Currently open trials in the same condition.
- NCT07128381 — Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Pat · Phase 1, PHASE2 · recruiting
- NCT06950034 — A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML) · Phase 1 · recruiting
- NCT03613532 — Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN · Phase 1 · active not recruiting
Other Peking University People's Hospital trials
Trials by the same sponsor.
- NCT07535645 — Baricitinib for Post-HSCT Persistent Thrombocytopenia · Phase 1, PHASE2 · not yet recruiting
- NCT07516002 — Immunoglobulin Efficacy and Immune Profiling in Antibody Immunodeficiency · not yet recruiting
- NCT07294339 — A Randomized Controlled Trial of Acupuncture for the Management of Hot Flashes in Patients With Hormone Receptor-Positiv · NA · not yet recruiting
- NCT07500441 — Digital PCR of CHIP and MR for MRD Monitoring After Allo-HSCT in AML · recruiting
- NCT07487883 — Cadherin 3(CDH3)-Targeted PET in Lung Malignant Tumors · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07113730 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Peking University People's Hospital
- Last refreshed: 15 August 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07113730.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing